Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.33 |
| ▸ | PDE9A | O76083 | 2/20 | 0.32 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.30 |
| ▸ | USP9X | Q93008 | 1/20 | 0.30 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21024952 | 0.85 | LRRK2 (0.33) | EPHX2CYP2D6HRH1KCNH2ELOVL1 | |
| SCHEMBL57030 | 0.81 | — | — | |
| Hydrochloric Acid SCHEMBL28314935 | 0.79 | — | — | |
| SCHEMBL13890730 | 0.77 | — | — | |
| SCHEMBL574344 | 0.77 | EPHX2 (0.38) | EPHX2CYP2D6HRH1KCNH2ELOVL1 | |
| SCHEMBL14722189 | 0.77 | EPHX2 (0.33) | EPHX2CYP2D6HRH1KCNH2ELOVL1 | |
| SCHEMBL2382273 | 0.75 | EPHX2 (0.38) | EPHX2CYP2D6HRH1KCNH2ELOVL1 | |
| SCHEMBL3434555 | 0.75 | EPHX2 (0.38) | EPHX2CYP2D6HRH1KCNH2ELOVL1 | |
| SCHEMBL29774585 | 0.75 | CYP2D6 (0.37) | EPHX2CYP2D6HRH1KCNH2LRRK2 | |
| SCHEMBL30066593 | 0.74 | EPHX2 (0.41) | EPHX2CYP2D6HRH1KCNH2ELOVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2023-04-27 | — | — | US | disclosed |
| CN-110713489-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-05-31 | — | — | CN | disclosed |
| CN-110183440-B | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2022-04-22 | — | — | CN | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| US-10947243-B2 | Heteroaryl SYK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2021-03-16 | — | — | US | disclosed |
| CN-110713489-A | Heteroaryl SYK inhibitors | 勃林格殷格翰国际有限公司 | 2020-01-21 | — | — | CN | disclosed |
| CN-106255689-B | Heteroaryl SYK Inhibitors | 勃林格殷格翰国际有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-110183440-A | Heteroaryl SYK inhibitor | 勃林格殷格翰国际有限公司 | 2019-08-30 | — | — | CN | disclosed |
| EP-3119765-B1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-07-17 | — | — | EP | disclosed |
| EP-3119772-B1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2019-05-22 | — | — | EP | disclosed |
| EP-3119765-A1 | HETEROARYL SYK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2017-01-25 | — | — | EP | disclosed |
| CN-106255689-A | Heteroaryl syk inhibitors | 勃林格殷格翰国际有限公司 | 2016-12-21 | — | — | CN | disclosed |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | EVOTEC (UK) LTD. (GB) | 2016-08-25 | — | — | US | disclosed |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | EVOTEC (UK) LTD. (GB) | 2016-08-25 | — | — | US | disclosed |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | EVOTEC (UK) LTD. (GB) | 2016-08-25 | — | — | US | disclosed |
| WO-2015140054-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140051-A1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140054-A1 | HETEROARYL SYK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
| WO-2015140051-A1 | HETEROARYL SIK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-09-24 | — | — | WO | disclosed |
| CN-102227425-A | Azaindazole compounds as ccr1 receptor antagonists | BOEHRINGER INGELHEIM INT | 2011-10-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947243-B2 | Heteroaryl SYK inhibitors | SYK, BTK, CD40 | EPHX2 1466/4885CYP2D6 2124/4885HRH1 61/4885 |
| US-20230127839-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | EPHX2 1579/4885CYP2D6 4347/4885HRH1 698/4885 |
| US-20160244446-A1 | HETEROARYL SYK INHIBITORS | SYK, BTK, IRAK1 | EPHX2 1810/4885CYP2D6 2002/4885HRH1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.